16 / 29
Euro Gastroenterology 2019 & Clinical Pharmacy 2019
Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3
Page 37
March 25-26, 2019 | Amsterdam, Netherlands
&
GASTROENTEROLOGY AND HEPATOLOGY
4
th
International Conference on
CLINICAL PHARMACY & PHARMACY PRACTICE
9
th
World Congress on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
THE HEPATOPROTECTIVE EFFECT’S RESULT OF NEW DRUG LONAL IN
PATIENT WITH NON-ALCOHOLIC FATTY LIVER DISEASE CONCOMITANT WITH
CHRONIC HEPATITIS
B Altanshagai
3
, Z Ariunaa
1
, Ts Sarnai
2
and
B Myagmarnaran
4
1
Treatment, Research and Production Company of The Mong-Em, Mongolia
2
Mongolian National University of Medicinal Sciences, Mongolia
3
New Medicine Medical University of Mongolia, Mongolia
4
Mongolian University of Pharmaceutical Science, Mongolia
Introduction:
Following researchers determined the Chronic hepatitis C virus infection which was 8,2% (Davaalkham.J
et al, 2003), 9,6% (Takahashi.M et al, 2004), 9,8% (Tsatsralt-Od.B et al, 2006), 11,8%
(Dagvadorj.Yaet al 2005) in Mongolia.
As researchers noted that hepatitis C genotype 1 and 3 enable to be triglyceride accumulation for liver because it often
occurs simultaneously fatty liver disease. Although many types of traditional medicine have been used for for hundreds
years, their effectiveness of the therapy is relatively small with inadequate use of poorly understood in practice. These
types of medicine’s storage, form, flavor are to improve which are prepared based on scientific studying, is to make the
clinical trial of drug acts as easily use, emerged as one of the need for market. Therefore, our research team has made the
clinical trial based on the chemical and pharmacological study of hepatoprotective effect for lonicera Altaica Pall fruit, an
established clinical study and producing new drugs.
Material and Method:
The research was considered such as clinical trial guideline for new drug issued by the WHO’s
“Good Clinical Practice”. Based on permission given by Biomedical Ethical Community of the Health Ministry of Mongolia
approved diagnosis patient with fatty liver disease associated with chronic hepatitis C. Research design is randomized
placebo-controlled, double blind clinical trial. We studied 3 groups of participants that was given the following treat-
ment for 21 days: (I) Treatment group: Lonal drug 1.4 gr ×3 times, (II) Control group: Silymarin drug 67.5 mg ×3 times, (III)
Placebo group: Placebo drug 1.4 gr ×3 times. We used on histo-morphometric analysis of liver biopsy DISKUS ver 4.80,
Olympus BX microscopy.
Results:
Lonal drug decreases activation of syndrome hepatic cell cytolysis ALT (p=0.023), AST (p=0.037). Also decreases
criteria of cholestasic syndrome such as indirect bilirubin (p=0.611), ALP (p=0.04), GGT (p=0.445). The lonal medicine was
taken during 21 days and comparing the results of lipid metabolism exchange before and after treatment, reduces TG
(p=0,402), increases HDL (p=0.047). The participants have taken the fibroscan analysis and liver biopsy. That was com-
pared to determine before and after treatment such as steatosis and fibrosis degree. Before treatment degree of steatosis
was S2: 278.4±75.3 dB/m and after treatment it was dropped from S1: 238.6±70.4 dB/m (p <0.05). And before treatment,
such as fibrosis degree F2-3: 8.84 ± 2.2 kPa, after treatment it was decreased in F1-2: 7.18 ± 3.87 (p<0.01). In liver histology,
comparing before and after treatment the results of liver cell inflammation-fibrosis area was reduced by 1,75 times and
decreases hepatic steatosis degree (strong fatty change was improved mild fatty change).
Conclusion:
New lonal medicine is reducing activation syndrome hepatic cell cytolysis, cholestatic and some criteria of
the metabolic syndrome in patient with fatty liver disease associated with chronic hepatitis C. Also new lonal medicine
reduces the degree of liver steatosis and fibrosis by the analysis of fibroscan and liver biopsy.
B Altanshagai et al., Arch Gen Intern Med 2019, Volume 3 | DOI: 10.4066/2591-7951-C1-023